A Phase 2 interventional study of Andecaliximab and Placebo in Cystic Fibrosis, sponsored by Gilead Sciences. Terminated at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-17.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Cystic Fibrosis by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Cystic Fibrosis · Gilead Sciences.
Among the 22 studies in Cystic Fibrosis by Gilead Sciences, this one is the 18th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2016, is one of 4 in phase 2, and was the 21st registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 22 studies in Cystic Fibrosis by Gilead Sciences is open now. The open studies under Cystic Fibrosis, anywhere →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 105 across the 19 interventional studies, 510 across the 1 observational. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Cystic Fibrosis by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of andecaliximab (GS-5745) on pre-bronchodilator forced expiratory volume in 1 second (FEV1) % predicted in adults with cystic fibrosis (CF) after 8 weeks of treatment.
There will be 2 parts to this study. In Part 1, andecaliximab 600 mg or placebo will be administered for 8 weeks. In Part 2, andecaliximab 300 mg, 150 mg, or placebo will be administered for 8 weeks. Part 2 will be initiated after completion of Part 1.
Key Inclusion Criteria:
Two pre-bronchodilator spirometry measures during screening and baseline must meet the following 2 criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Andecaliximab 600 mg weekly for 8 weeks
Drug: Andecaliximab
Placebo weekly for 8 weeks
Drug: Placebo
Andecaliximab 300 mg weekly for 8 weeks
Drug: Andecaliximab
Andecaliximab 150 mg + placebo weekly for 8 weeks
Drug: Andecaliximab · Drug: Placebo
Placebo weekly for 8 weeks
Drug: Placebo
(Part 1) Andecaliximab 600 mg weekly for 16 weeks; (Part 2) Andecaliximab 300 mg weekly for 16 weeks
Drug: Andecaliximab
Administered via subcutaneous injection
Also known as: GS-5745
Administered via subcutaneous injection
Absolute Change in Pre-bronchodilator FEV1 Percent Predicted From Baseline to Week 8
Time frame: Baseline; Week 8
Absolute Change in Post-bronchodilator FEV1 Percent Predicted From Baseline to Week 8
Time frame: Baseline; Week 8
Relative Change in Pre-bronchodilator FEV1 Percent Predicted From Baseline to Week 8
Time frame: Baseline; Week 8
Relative Change in Post-bronchodilator FEV1 Percent Predicted From Baseline to Week 8
Time frame: Baseline; Week 8
Participants were enrolled at study sites in Australia and Europe. The first participant was screened on 04 November 2016. The last study visit occurred on 21 July 2017. The study was terminated after 6 participants were enrolled in Part 1 of the study. Therefore, Part 2 was not initiated.
| Milestone | Andecaliximab | Placebo |
|---|---|---|
| Started | 3 | 3 |
| Completed | 3 | 3 |
| Not completed | 0 | 0 |
| Milestone | Andecaliximab | Placebo |
|---|---|---|
| Started | 2 | 2 |
| Completed | 0 | 0 |
| Not completed | 2 | 2 |
| Withdrew: Withdrew consent | 1 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 2 |
| percent | Andecaliximab | Placebo |
|---|---|---|
| Absolute Change in Pre-bronchodilator FEV1 Percent Predicted From Baseline to Week 8 | -2.10 ± 4.446 | 2.90 ± 3.461 |
| percent | Andecaliximab | Placebo |
|---|---|---|
| Absolute Change in Post-bronchodilator FEV1 Percent Predicted From Baseline to Week 8 | 1.01 ± 4.534 | -1.45 ± 1.655 |
| percent change | Andecaliximab | Placebo |
|---|---|---|
| Relative Change in Pre-bronchodilator FEV1 Percent Predicted From Baseline to Week 8 | -3.85 ± 9.009 | 4.41 ± 4.196 |
| percent change | Andecaliximab | Placebo |
|---|---|---|
| Relative Change in Post-bronchodilator FEV1 Percent Predicted From Baseline to Week 8 | 2.28 ± 9.323 | -1.98 ± 1.749 |
Collected over Baseline up to the last dose date plus 30 days (maximum exposure: 140 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Andecaliximab (Double-Blind) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Placebo (Double-Blind) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Andecaliximab (Open-Label) | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | Andecaliximab (Double-Blind) | Placebo (Double-Blind) | Andecaliximab (Open-Label) |
|---|---|---|---|
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 | 2/4 |
| Cystic fibrosisCongenital, familial and genetic disorders | 1/3 | 0/3 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 0/3 | 0/4 |
| GastritisGastrointestinal disorders | 0/3 | 1/3 | 0/4 |
| Injection site bruisingGeneral disorders | 0/3 | 1/3 | 0/4 |
| Injection site erythemaGeneral disorders | 1/3 | 0/3 | 0/4 |
| Injection site haematomaGeneral disorders | 0/3 | 1/3 | 0/4 |
| Injection site painGeneral disorders | 1/3 | 0/3 | 0/4 |
| Injection site pruritusGeneral disorders | 1/3 | 1/3 | 0/4 |
| RhinitisInfections and infestations | 0/3 | 1/3 | 0/4 |
Safety Analysis Set: participants who took at least 1 dose of study drug.
| Age, Continuous(years) | Andecaliximab | Placebo | Total |
|---|---|---|---|
| Mean | 46.0 ± 20.42 | 43.3 ± 10.02 | 44.7 ± 14.46 |
| Sex: Female, Male(Participants) | Andecaliximab | Placebo | Total |
|---|---|---|---|
| Female | 2 | 0 | 2 |
| Male | 1 | 3 | 4 |
| Race/Ethnicity, Customized(Participants) | Andecaliximab | Placebo | Total |
|---|---|---|---|
| White | 3 | 3 | 6 |
| Race/Ethnicity, Customized(Participants) | Andecaliximab | Placebo | Total |
|---|---|---|---|
| Not Hispanic or Latino | 3 | 3 | 6 |
| Region of Enrollment(Participants) | Andecaliximab | Placebo | Total |
|---|---|---|---|
| United Kingdom | 1 | 1 | 2 |
| Australia | 1 | 0 | 1 |
| France | 0 | 1 | 1 |
| Germany | 0 | 1 | 1 |
| Spain | 1 | 0 | 1 |
| Pre-bronchodilator Forced expiratory volume in 1 second (FEV1) % predicted(percent) | Andecaliximab | Placebo | Total |
|---|---|---|---|
| Mean | 49.7 ± 8.70 | 59.1 ± 19.26 | 54.4 ± 14.33 |
| Post-bronchodilator FEV1 % predicted(percent) | Andecaliximab | Placebo | Total |
|---|---|---|---|
| Mean | 52.1 ± 5.90 | 64.6 ± 20.58 | 58.3 ± 15.17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Jul 2017, 8 months.
Results were first posted in Jul 2018, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Andecaliximab